Federal Agency · National Institutes of Health
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Last updated: October 15, 2026
Posted October 15, 2024
Funding
Up to $250K
Closes
October 14, 2026
NAICS
541714
Similar grants still open
- FY2026 Implementation of the Quagga and Zebra Mussel Action Plan (QZAP) in the Western United StatesFish and Wildlife Service · closes October 24, 2026
- Assisting Specialty Crop Exports: Low Oxygen Storage and Packaging Systems for U.S. Tree Nuts with Phytosanitary TraceabilityForeign Agricultural Service · closes October 26, 2026
- Climate Program Office (CPO) FY2026 Earth System Science and Services PartnershipDOC NOAA - ERA Production · closes October 26, 2026
- Long-term health outcomes of people living with spina bifidaCenters for Disease Control - NCBDDD · closes October 26, 2026
- ROSES25: D.8 Habitable Worlds Observatory Precursor Science InvestigationNASA Headquarters · closes October 26, 2026
- Strengthening Bosnia and Herzegovina’s Organized Crime Specialized Departments for Organized Crime Through Expert Advisory SupportU.S. Mission to Bosnia and Herzegovina · closes October 27, 2026
- OJP FY 2026 Special Attorneys Program Round 10Bureau of Justice Assistance · closes October 28, 2026
- NASA Innovative Advanced Concepts (NIAC) Phase INASA Headquarters · closes October 28, 2026
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.
Eligibility
- Funded by NIH
Award details
Award range: Up to $250K. Applications close on October 14, 2026.
Categories
Not categorized
This grant is no longer accepting applications. Get matched to open grants like it, or browse the ones above.
See similar open grants ↑Applications closed — listing kept for reference.·Source: Grants.gov·Last seen Oct 13, 2026